摘要:
In der vorliegenden Erfindung werden Peptide abgeleitet von Exendin-3 bereitgestellt, die an den GLP-1-Rezeptor binden und unmarkiert oder markiert zur Herstellung eines Mittels zur Diagnostik und Therapie gut- und bösartiger Erkrankungen, bei denen die GLP-1 Rezeptorexpression eine Rolle spielt, eingesetzt werden.
摘要:
The invention relates to a method for producing C-terminal amidated dibasic or polybasic peptides, consisting in reacting two peptides in the presence of trypsin biologically active enzymes and, if necessary, in purifying the thus obtainable compounds of formula (I) by means of protein chemistry.
摘要:
The present invention is related to the use of variants of the Pituitary Adenylate Cyctase-Activating Polypeptide (PACAP) to stimulate the growth and to improve the immunological system of aquatic organisms. The variants of the peptide were provided by immersion, injection or as a food additive.
摘要:
The present invention relates to a population of insulin producing cells made by a process comprising contacting non-insulin producing cells with a growth factor selected from the group consisting of GLP-1 or Exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or Exendin-4, and fragments thereof. The present invention also relates to methods of differentiating non-insulin producing cells into insulin producing cells and of enriching a population of cells for insulin-producing cells. The present invention also relates to methods of treating diabetes.
摘要:
Exendin 4 polypeptide fragments having blood sugar lowering action which can be used for treating type II diabetes are provided. The polypeptide fragments have the sequence of HGEGTX1TSDLSKQX2EEEAVX3LFIEWLKNGX4PX5, wherein X1 represents Phe or Tyr, X2 represents Met, Ile or Leu, X3 represents Lys, X4 represents Gly or deletion, and X5 represents Arg or deletion. The process for preparing the Exendin 4 polypeptide fragments is also provided.
摘要:
In der vorliegenden Erfindung werden Peptide abgeleitet von Exendin-3 und/oder Exendin-4 bereitgestellt, die an den GLP-1-Rezeptor binden und unmarkiert oder markiert zur Herstellung eines Mittels zur Diagnostik und Therapie gut- und bösartiger Erkrankungen, bei denen die GLP-1 Rezeptorexpression eine Rolle spielt, eingesetzt werden.